New hope for myelofibrosis: experimental combo targets Drug-Resistant patients
Disease control
Recruiting now
This early-stage trial is testing whether adding roginolisib to the standard drug ruxolitinib is safe and tolerable for adults with myelofibrosis whose disease no longer responds to JAK inhibitors. The study will enroll 26 participants and monitor side effects, heart changes, and…
Phase: PHASE1, PHASE2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC